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ments the mortality reductions observed with early ART initiation
in all other HIV-TB co-infected patients.
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Background: Mantoux test was introduced over century ago, is
till usedas a laboratory test in epidemiological studiesofMycobac-
erium tuberculosis infection (MTI) in most developing countries.
antoux test is based on simple application but it could be lim-
ted by high false positive results. The cost limits the application
f newer techniques. Therefore, we analyzed retrospectively the
antoux test positivity in relation to clinical details suspected of
TI over 5-year period.
Methods: The 5-year retrospective study was carried out in the
epartment of Immunology and Infectious Diseases, University of
aiduguri Teaching Hospital, between 1999-2003. Data extracted
ere of patientswith various clinical details of whichMantoux test
equested. Mantuox test induration diameter of > 5mm is scored
ositive.
Results: Of 3218 patients examined, positive results recorded
n 1532 (47.6%): 980 (30.1%) males and 562 (17.5%) females.
ge-group distribution, 21-40 (27.0%), < 20 (11.6%), 41-60 (7.2%)
nd>60 years (1.7) (p <0.05). Mantoux induration diameter, 10-
5mm (24.2%), >15mm (15.8%) and 5-9mm (7.6%) (p <0.05). Of
7 classiﬁed clinical details examined, positive Mantoux reactions
ere recorded in 13 cases (76.5%, 13/17). Pulmonary tubercu-
osis (518/1074, 48.2%), extra pulmonary tuberculosis (146/270,
4.1%), Pott’s diseases (144/236, 61.0%), low back pain (94/132,
1.2%), orthoarthritis (26/42, 61.9%), retroviral infection (60/142,
2.3%), cervical lymphadenitis (24/44, 54.5%), fever/rashes (2/10,
6.7%), bronchopneumonia (54/184, 29.0%), weight loss (154/404,
7.6%), lymph node enlargement (26/54, 48.1%), others (186/428,
3.0%) and routine examination (100/160, 62.5%). Comparison of
ther details with PTB indicates that possibility of Mantoux test
ositivity is higher in Pott’s disease [OR (95% CI) = 1.33 (1.12-
.57), p =0.0001], Low back pain [OR (95%CI) = 1.80(1.367—2.36),
= 0.0001], and routine examination [OR (95%CI) = 1.38 (1.121-
.70),p =0.001], while it is similar in extra-pulmonary tuber-
ulosis [OR (95%CI) = 1.13 (0.98-1.29),p =0.089], orthoarthritis
OR (95%CI) = 1.36 (0.92-2.01), p =0.086], retroviral infection [OR
95%CI) = 0.90 (0.77-1.04),p =0.21], cervical lymphadenitis [OR
95%CI) = 1.14 (0.82-1.58),p =0.44], lymph nodes enlargement [OR
95%CI) = 1.00 (0.77-1.30), p =0.99].
Conclusion: High Mantoux test positivity was recorded in
iverse clinical details examined indicating different clinical pre-
entations of MTI. Thus, utilization of this laboratory test should be
ollaborated with clinical indices and other tests to guide against
alse-positive results.
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Background: South Africa has the fourth highest burden of
multi-drug resistant tuberculosis (MDR TB) globally, further com-
plicated by the highprevalence ofHIV co-infection resulting in high
morbidity andmortality. This study assessed the impact of combin-
ing antiretroviral therapy (ART) with TB treatment, on mortality in
HIV-infected patients with MDR TB.
Methods: In the SAPiT (Starting Antiretroviral therapy at three
Points in TB treatment) study, a randomised controlled trial of
HIV–TB coinfected patients, sputum culture and susceptibility for
Mycobacterium tuberculosis was performed on 489 of the 642
patients enrolled. A sub-group of 23 (4.7%) patients with MDR
TB (resistance to at least isoniazid and rifampin) were identiﬁed.
Clinical outcomes at 18 months of follow-up were compared in
patients randomized to receive ART within 4-12 weeks of tuber-
culosis treatment initiation (combined integrated treatment arm),
with those who commenced ART after completing tuberculosis
treatment (sequential treatment arm). The primary endpoint was
death.
Results: Demographic, clinical and laboratory characteristics of
14 patients in the combined integrated treatment arm and the 9
patients in the sequential treatment arm with MDR TB were simi-
lar. The incidence rate of death was 11.8 (2/14) and 56.0 (5/9) per
100 person-years in the combined integrated treatment arm and
sequential treatment arm respectively (IRR0.21; 95%CI: 0.02–1.29;
P=0.06).
Conclusion: Early ART initiation in TB patients with MDR TB
reduced mortality despite late diagnosis and late initiation of
appropriate treatment of theMDRTB. This survival beneﬁt comple-
